QUOTE AND NEWS
SeekingAlpha  Jun 24  Comment 
By JMY Investments: After years of monetary pain from being too early investing in developmental-stage stem cell biotech, investors are finally seeing some gains as the science, which showed huge promise in preclinical studies, is now being...
SeekingAlpha  Jun 12  Comment 
By Jason Napodano: We recently took a detailed look at BrainStorm Cell Therapeutics, Inc. (OTCQB:BCLI). BrainStorm is a biotechnology company developing adult stem cell therapies for a range of neurodegenerative diseases, including Amyotrophic...
StreetInsider.com  Mar 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Cell+Therapeutics+Inc.+%28CTIC%29+Posts+Surprise+Q4+Profit+of+8cShare/9244204.html for the full story.
SeekingAlpha  Jan 6  Comment 
By BioGroup Team: By Roy Vimer, BA, and Nir Etkovitz, PhD The end of 2013 brought much-awaited relief to Cell Therapeutics Inc. (CTIC) investors. In the past few months, Cell Therapeutics Inc. (CTI) announced a joint international agreement...
DailyFinance  Jan 6  Comment 
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced the upcoming publication of a case report on an individual patient treated...
StreetInsider.com  Nov 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Cell+Therapeutics+Inc.+%28CTIC%29+Narrows+Q3+Loss+to+38cShare/7833002.html for the full story.
StreetInsider.com  Aug 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Cell+Therapeutics+Inc.+%28CTIC%29+Widens+Q2+Loss+to+28cShare/7620340.html for the full story.
StreetInsider.com  Jul 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Cell+Therapeutics%2C+Inc.+%28CTIC%29+Narrows+Q2+Loss/6665614.html for the full story.
StreetInsider.com  Jun 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Cell+Therapeutics+%28CTICD%29+Regains+Nasdaq+Listing+Compliance/6550504.html for the full story.
Wall Street Sector Selector  May 26  Comment 
Cell Therapeutics, Inc. (NASDAQ: CTICD) has long been a controversial stock.  It has brought many rewards for investors and it has also brought much pain to investors.  We recently featured its positive development in pixantrone with an appeal...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki